#1 Clinical Trials Search in Europe

Study on the Safety and Effectiveness of tolDC for Patients with Relapsing Remitting and Progressive Multiple Sclerosis

2 1 1

What is this study about?

This clinical trial is focused on studying the disease known as Multiple Sclerosis (MS), which affects the brain and spinal cord, leading to a range of symptoms such as fatigue, difficulty walking, and vision problems. The treatment being tested in this study is called tolDC, which is a type of cell therapy. This treatment involves using special cells called dendritic cells, which are taken from the patient’s own blood and modified outside the body to help the immune system work better. These cells are then injected back into the patient through a method called intradermal injection, which means the injection is given just under the skin.

The purpose of this study is to evaluate the safety and effectiveness of this new treatment in patients with two types of MS: Relapsing Remitting MS and Progressive MS. The study will involve patients receiving the tolDC treatment, while some may receive a placebo. The trial will monitor the number of new or growing lesions in the brain using MRI scans, which are detailed images of the brain, to see how well the treatment is working. Additionally, the study will track any side effects and changes in the frequency of relapses, which are periods when symptoms get worse.

Participants in the study will be observed over a period of time to assess changes in their condition, including any improvements in their symptoms or overall health. The study aims to provide valuable information on whether tolDC can be a safe and effective treatment option for people living with Multiple Sclerosis. The trial is expected to continue until 2027, with recruitment starting in 2025.

1 joining the study

Upon joining the study, eligibility is confirmed based on criteria such as age, diagnosis of Multiple Sclerosis (MS), and ability to comply with the protocol.

Participants must have appropriate venous access and agree to use adequate contraceptive measures if of reproductive potential.

2 initial assessment

An initial assessment is conducted to establish baseline health status, including a review of medical history and a physical examination.

MRI scans are performed to evaluate the presence of new or enlarging T2 lesions, which are areas of damage in the brain.

3 treatment administration

Participants receive the treatment, which involves an intradermal injection of myelin peptide-loaded tolDC.

The treatment is administered according to a schedule determined by the study protocol.

4 monitoring and follow-up

Regular follow-up visits are scheduled to monitor the participant’s health and response to the treatment.

MRI scans are repeated to assess changes in T2 lesions and other brain structures.

5 evaluation of outcomes

The primary outcome is evaluated by the number of new and enlarging T2 lesions on MRI scans.

Secondary outcomes include the number and severity of adverse events, proportion of relapse-free patients, and changes in relapse rate and disability scores.

6 completion of the study

The study is estimated to conclude by October 2027.

Final assessments are conducted to determine the overall efficacy and safety of the treatment.

Who Can Join the Study?

  • Have a diagnosis of Multiple Sclerosis (MS) according to the most recent guidelines.
  • Be able to follow the study’s procedures and assessments.
  • Have suitable veins for blood tests and treatments.
  • Use effective birth control methods during the study if you can have children. This applies to both men and women. Accepted methods include hormonal contraceptives (like pills or patches), intrauterine devices, sterilization, being postmenopausal, or using condoms with spermicide.
  • Be between 18 and 60 years old.
  • Have a score between 0 and 6.0 on the Expanded Disability Status Scale (EDSS), which measures disability in MS.
  • Have active MS, meaning at least one relapse in the past year, or at least one new or growing lesion on a brain scan in the past year.
  • Be either on first-line treatment for MS or not receiving treatment due to side effects or personal choice.
  • Have no MS relapse in the month before starting the study and during the initial screening phase.
  • Have a normal total count of lymphocytes, which are a type of white blood cell.
  • Have a normal count of peripheral B cells, another type of white blood cell.
  • Be able to understand and sign a consent form agreeing to participate in the study.

Who Cannot Join the Study?

  • Patients who are not diagnosed with Multiple Sclerosis cannot participate. Multiple Sclerosis is a condition that affects the brain and spinal cord.
  • Patients who are not within the specified age range for the study cannot participate. The age range is not specified here, but it is important for eligibility.
  • Patients who are part of a vulnerable population cannot participate. A vulnerable population includes groups that may need special protection, like children or people with certain disabilities.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

No sites found in this category

Other Sites

Site Name City Country Status
Uvgbdzopie Og Aybgppv Edegem Belgium
Hmrheicb Uzqzpdvtdeybf Hqkjohxa Tnmng y Pqftdc Ipjikrzm Ckgchy dxmdqsyxlyhikhytz (ckbo Badalona Spain

Want to learn more about this study or check if you can participate? Contact us.

Trial status

Country Status Recruitment Start
Belgium Belgium
Not recruiting
01.01.2025
Spain Spain
Not recruiting
01.01.2025

Trial locations

Investigated drugs:

Myelin Peptide-Loaded tolDC is an experimental therapy being tested for its safety and effectiveness in treating Multiple Sclerosis (MS). This therapy involves using dendritic cells (tolDC) that are loaded with myelin peptides. These cells are specially prepared in a laboratory following strict manufacturing standards. The goal is to help the immune system better manage the disease by potentially reducing the frequency and severity of MS relapses and slowing down disease progression.

Investigated diseases:

Multiple Sclerosis – Multiple Sclerosis is a chronic disease that affects the central nervous system, particularly the brain and spinal cord. It is characterized by the immune system mistakenly attacking the protective sheath (myelin) that covers nerve fibers, leading to communication problems between the brain and the rest of the body. Over time, the disease can cause permanent damage or deterioration of the nerves themselves. Symptoms can vary widely, depending on the amount of nerve damage and which nerves are affected, and may include fatigue, difficulty walking, numbness or tingling, muscle weakness, and problems with coordination and balance. The disease often progresses with periods of relapses and remissions, or it may steadily worsen over time. There are different types of Multiple Sclerosis, including Relapsing-Remitting and Progressive forms, each with its own pattern of progression.

Trial ID:
2024-512891-37-00
Trial Phase:
Therapeutic exploratory (Phase II)

Other Trials to Consider

  • A study to compare the effectiveness and safety of subcutaneous frexalimab versus intravenous frexalimab in adults with multiple sclerosis

    Recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Italy Spain

  • A Study Comparing Two Forms of Ocrelizumab Given Under the Skin in Patients with Multiple Sclerosis

    Recruiting

    2 1 1 1
    Investigated drugs:
    France Germany Italy Poland Spain